Reza Halse
Partner @ Partners Innovation Fund
London, United Kingdom
Reza Halse is a Series A investor at Partners Innovation Fund in London focused on Biotechnology and Health Care. Reza Halse - Partner, RA Ventures @ RA Capital Management
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Reza Halse invests in
Stages Reza Halse invests in
Countries Reza Halse invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Therapeutics 4 (50%)
- Medical Device 1 (13%)
- Information Technology 1 (13%)
Stage
- Series A 4 (50%)
- Seed 2 (25%)
Country
- United States 4 (50%)
- Denmark 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $34M / Series A / Apr 04, 2023 | ||
| ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $61.8M / Series A / Apr 29, 2021 | ||
| Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M / Series A / Nov 26, 2018 | ||
| Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $30M / Series A / Jun 08, 2015 | ||
| Raze Therapeutics is leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways. Raze is advancing a pipeline of therapeutics based on new biological insights into how cancer cells reprogram metabolism to activate central anabolic processes essential for tumors to grow and survive. | $24M / Series A / Oct 14, 2014 | ||
| Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $4.8M / Seed / May 12, 2014 | ||
| Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $3M / Series A / Apr 09, 2014 | ||
| Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | Seed / Dec 31, 2013 |
Co-Investors
About Partners Innovation Fund
The Innovation Fund was created in 2007 by Brigham and Women's Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development.The main objective of the fund is to accelerate to market technologies developed by Partners HealthCareinvestigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments.Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia.The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success.The Fund has four major goals:* Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare.* Provide funding for technologies positioned in the capital gap between invention and clinical development.* By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment.* Generate a return on investment to refresh the fund and provide capital for additional technologies.Gap FundingOver the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk.Types of Fund InvestmentsThe Partners Innovation Fund will make two types of investments: Equity and Development.Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds.Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player.For all investments, funds will be reserved for participation in follow-on investments.Innovation Fund ProcessUtilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps:1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are:* Product concept and value proposition* Intellectual Property Position* Stage of technology development* Market Opportunity* Technology Review* Management Team* Regulatory pathway* Funding requirements* Competitive Analysis* Business Model 2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval.The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena.Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.
Partners Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anne C. Pareti
Associate II
|
|||
Ellen Jung
Associate II
|
|||
Jessica M. Jacobs
Associate, Research & Licensing
|
|||
Michael Band
Manager, Business Development
|
|||
|
Pamela Keddy
Executive Assistant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Reza Halse invest in?
Reza Halse invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Reza Halse?
Public channels for Reza Halse include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Reza Halse last invest?
The most recent investment recorded for Reza Halse closed in Apr 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
